SCHEMBL21201010

SCHEMBL21201010

CC(=O)OC(C)c1ccnc(Br)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.35
CYP17A1 P05093 2/20 0.35
KDM1A O60341 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
AR P10275 4/20 0.33
TSHR P16473 2/20 0.33
CYP3A4 P08684 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ABCB11 O95342 1/20 0.33
LMNA P02545 1/20 0.33
ESR1 P03372 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2C9 P11712 1/20 0.33
PDE4A P27815 1/20 0.33
ADRA1A P35348 1/20 0.33
OPRK1 P41145 1/20 0.33
STAT6 P42226 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21200362 1.00 CYP19A1 (0.35) CYP19A1CYP17A1KDM1AHDAC1HDAC6
SCHEMBL29866369 1.00 CYP19A1 (0.35) CYP19A1CYP17A1KDM1AHDAC1HDAC6
SCHEMBL29102829 0.86 AR (0.35) CYP19A1CYP17A1KDM1AHDAC1HDAC6
SCHEMBL27752251 0.81 SMARCA2 (0.38) CYP19A1CYP17A1TSHRCYP3A4KDM4E
SCHEMBL27845906 0.76 KDM1A (0.37) KDM1AHDAC1HDAC6ARKDM4E
SCHEMBL10516365 0.75 CYP19A1 (0.54) CYP19A1CYP17A1TSHRCYP3A4USP2
SCHEMBL20719609 0.75 FDFT1 (0.34) CYP19A1CYP17A1TSHRCYP3A4KDM4E
SCHEMBL24031007 0.75 PTGS2 (0.46) TSHRCYP3A4KDM4ELMNAHIF1A
SCHEMBL8241576 0.75 KDM1A (0.36) KDM1AHDAC1HDAC6ARKDM4E
SCHEMBL25810655 0.74 PTGS1 (0.47) CYP19A1KDM1AHDAC1HDAC6AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 WO disclosed
CN-103403001-A Novel heterocyclic derivatives and their use in the treatment of neurological disorders NOVARTIS AG 2013-11-20 CN disclosed